Clinical relevance of systemic monocytic-MDSCs in patients with metastatic breast cancer
(2020) In Cancer Immunology, Immunotherapy 69(3). p.435-448- Abstract
The overall aim of this prospective study was to delineate the role of monocytic myeloid-derived suppressor cells (Mo-MDSCs) in patients with metastatic breast cancer (MBC). MDSCs are a heterogeneous group of immunosuppressive cells often enriched in different malignancies which hold prognostic and predictive value for clinical outcomes. Here, we assessed the clinical significance of Mo-MDSCs in 54 patients with de novo or distant recurrent MBC. We show that high levels of Mo-MDSCs significantly correlated with de novo MBC (metastatic disease at initial diagnosis), estrogen receptor (ER) negativity, and liver- and bone metastasis. A trend towards an association between high levels of Mo-MDSCs and survival (P = 0.053) was also found in... (More)
The overall aim of this prospective study was to delineate the role of monocytic myeloid-derived suppressor cells (Mo-MDSCs) in patients with metastatic breast cancer (MBC). MDSCs are a heterogeneous group of immunosuppressive cells often enriched in different malignancies which hold prognostic and predictive value for clinical outcomes. Here, we assessed the clinical significance of Mo-MDSCs in 54 patients with de novo or distant recurrent MBC. We show that high levels of Mo-MDSCs significantly correlated with de novo MBC (metastatic disease at initial diagnosis), estrogen receptor (ER) negativity, and liver- and bone metastasis. A trend towards an association between high levels of Mo-MDSCs and survival (P = 0.053) was also found in patients with distant recurrent ER-positive MBC. We therefore propose that an increased population of Mo-MDSCs may be related to the metastatic or immunoregulatory switch associated with transition to a more systemic disease. Our data imply that high levels of systemic Mo-MDSCs represent patients with more aggressive disease and worse outcome.
(Less)
- author
- Bergenfelz, Caroline LU ; Roxå, Anna ; Mehmeti, Meliha LU ; Leandersson, Karin LU and Larsson, Anna Maria LU
- organization
- publishing date
- 2020-03
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Breast cancer, Estrogen receptor, Metastasis, Mo-MDSCs, Survival
- in
- Cancer Immunology, Immunotherapy
- volume
- 69
- issue
- 3
- pages
- 14 pages
- publisher
- Springer
- external identifiers
-
- pmid:31925475
- scopus:85077708211
- ISSN
- 0340-7004
- DOI
- 10.1007/s00262-019-02472-z
- language
- English
- LU publication?
- yes
- id
- 6a1ee857-dd97-4869-a0fa-8f6d69b86aae
- date added to LUP
- 2020-01-28 08:55:56
- date last changed
- 2024-09-18 17:01:29
@article{6a1ee857-dd97-4869-a0fa-8f6d69b86aae, abstract = {{<p>The overall aim of this prospective study was to delineate the role of monocytic myeloid-derived suppressor cells (Mo-MDSCs) in patients with metastatic breast cancer (MBC). MDSCs are a heterogeneous group of immunosuppressive cells often enriched in different malignancies which hold prognostic and predictive value for clinical outcomes. Here, we assessed the clinical significance of Mo-MDSCs in 54 patients with de novo or distant recurrent MBC. We show that high levels of Mo-MDSCs significantly correlated with de novo MBC (metastatic disease at initial diagnosis), estrogen receptor (ER) negativity, and liver- and bone metastasis. A trend towards an association between high levels of Mo-MDSCs and survival (P = 0.053) was also found in patients with distant recurrent ER-positive MBC. We therefore propose that an increased population of Mo-MDSCs may be related to the metastatic or immunoregulatory switch associated with transition to a more systemic disease. Our data imply that high levels of systemic Mo-MDSCs represent patients with more aggressive disease and worse outcome.</p>}}, author = {{Bergenfelz, Caroline and Roxå, Anna and Mehmeti, Meliha and Leandersson, Karin and Larsson, Anna Maria}}, issn = {{0340-7004}}, keywords = {{Breast cancer; Estrogen receptor; Metastasis; Mo-MDSCs; Survival}}, language = {{eng}}, number = {{3}}, pages = {{435--448}}, publisher = {{Springer}}, series = {{Cancer Immunology, Immunotherapy}}, title = {{Clinical relevance of systemic monocytic-MDSCs in patients with metastatic breast cancer}}, url = {{http://dx.doi.org/10.1007/s00262-019-02472-z}}, doi = {{10.1007/s00262-019-02472-z}}, volume = {{69}}, year = {{2020}}, }